Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.

Trial Profile

Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesencephalic astrocyte-derived neurotrophic factor (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions

Most Recent Events

  • 14 May 2015 This trial in Parkinson's disease appears to have been withdrawn prior to enrolment, as Amarantus BioScience Holdings is targeting retinitis pigmentosa for first-in-man studies of mesencephalic astrocyte-derived growth factor, as reported in a media release.
  • 09 Jun 2011 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top